Meeting
2023 ASCO Annual Meeting
Validation of a single-cell sequencing assay for the detection of circulating tumor cells in metastatic breast cancer.
Authors
David Bourdon
Epic Sciences, San Diego, CA
David Bourdon , Tatjana Singer , Raj Srikrishnan , Alessandra Cunsolo , Ernest Lam , Nilesh Dharajiya , Rick Wenstrup , Martin Blankfard , Jason H. Christiansen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1053)
DOI
10.1200/JCO.2023.41.16_suppl.1053
Abstract #
1053
Poster Bd #
274
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.
First Author: Charlotte Andrieu
Poster
2022 ASCO Annual Meeting
ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).
First Author: Qiang Zhang
Poster
2022 ASCO Annual Meeting
Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA).
First Author: Lorenzo Gerratana
Poster
2022 ASCO Annual Meeting
CK+/CD45+ (dual-positive) circulating cells are associated with prognosis in patients with advanced breast cancer.
First Author: Carolina Reduzzi